Core Viewpoint - MicroPort Medical (00853) has seen its stock price rise by 8.68%, currently trading at HKD 11.02, with a transaction volume of HKD 1.60 billion. The company announced that the independent shareholders of MicroPort Cardiac have approved a merger agreement during a special meeting held on December 15, 2025, with the merger expected to be completed around December 19, 2025. This strategic merger aims to optimize resource allocation and enhance overall competitiveness in the structural heart disease and arrhythmia management sectors [1][4]. Group 1 - MicroPort Medical's stock price increased by 8.68% to HKD 11.02, with a trading volume of HKD 1.60 billion [1][4]. - The independent shareholders of MicroPort Cardiac approved the merger agreement on December 15, 2025, with completion expected around December 19, 2025 [1][4]. - All existing issued shares of CRM Cayman will be canceled in exchange for ordinary shares of MicroPort Cardiac, making CRM Cayman a wholly-owned subsidiary of MicroPort Cardiac [1][4]. Group 2 - The strategic merger is a key initiative for the company to optimize resource allocation and enhance overall competitiveness [1][4]. - The merger aims to strengthen synergies in the structural heart disease and arrhythmia management fields [1][4]. - By integrating complementary product lines and global channel resources, the company plans to accelerate market penetration and improve operational efficiency [1][4].
微创医疗现涨近9% 预期微创心通与CRM Cayman合并将于明日前后完成